Navigation Links
OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
Date:7/14/2008

ell lung, breast, ovarian, bladder, renal, pancreatic, anaplastic large cell lymphoma and colon cancers and melanoma. Increased clusterin production is linked to faster rates of cancer progression, treatment resistance and shorter survival duration. Clusterin levels may be further increased in response to standard cancer therapies, including hormone ablation therapy, chemotherapy and radiation therapy. Clusterin expression is linked to disease progression, treatment resistance, poor prognosis and survival in scientific publications. For example, increased expression of clusterin in prostate cancer is closely correlated with increasing Gleason score, which is a strong prognostic factor for poor survival of patients with prostate cancer.

About the Special Protocol Assessment and Agreement Process

Under a Special Protocol Assessment (SPA), a company and the FDA can reach an agreement on the design and size of a clinical trial to support a regulatory submission. This agreement can be in writing and cannot be changed after the clinical trial begins except: (i) with written agreement of the company and the FDA; or (ii) if the director of the FDA reviewing division determines that "a substantial scientific issue essential to determining the safety or effectiveness of the drug" was identified after testing began.

About OncoGenex

OncoGenex is a private biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. The company's three product candidates are designed to inhibit the production of specific proteins associated with treatment resistance and which are over-produced in response to a variety of cancer treatments. OGX-011 is completing evaluation in five Phase 2 clinical studies in prostate, lung, and breast cancers. OGX-427 has begun evaluation in Phase 1 clinical studies, while the third product candidate, OGX-225, has completed preclinical pharmac
'/>"/>

SOURCE OncoGenex Technologies Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. OncoGenex increases economic interest in lead cancer drug OGX-011
2. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
3. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
4. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
5. CV Therapeutics Receives European Marketing Authorization for Ranolazine for the Treatment of Patients With Chronic Angina
6. Epeius Biotechnologies Tumor-Targeted Rexin-G Receives FDA Orphan Drug Designation for the Treatment of Osteosarcoma
7. Edison Pharmaceuticals Receives Commendation From the City of San Jose
8. GeneraMedix Inc. Receives Approval for Epoprostenol for Injection 1.5 mg
9. Microfluidic Systems Receives Continued Funding From the Department of Homeland Security (DHS) Toward the Commercial Production of Autonomous Airborne Pathogen Detection Systems
10. Par Pharmaceutical Receives Final Approval to Market Generic Marinol(R) CIII (Dronabinol) Capsules
11. Indevus Receives Approvable Letter from FDA for NEBIDO(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 30, 2015 AACC welcomed thousands of ... AACC Annual Meeting & Clinical Lab Expo in ... The meeting showcased revolutionary advancements in clinical testing ... healthcare providers to diagnose patients quickly and accurately ... As of Wednesday, July 29, ...
(Date:7/30/2015)... CAMBRIDGE, Mass. , July 30, 2015 /PRNewswire/ ... software solutions for the interpretation and analysis of ... Matthew Fischer has joined the company ... Photo - http://photos.prnewswire.com/prnh/20150730/250931 ... astounding capabilities to integrate, interpret, analyze and explore ...
(Date:7/30/2015)... Dallas, TX, USA (PRWEB) , ... July 30, ... ... nano and microsystems, has appointed Francois Vieillard as Sales & Marketing Director. ... executive positions, Francois Vieillard will be responsible for reinforcing Tronics’ business development activities ...
(Date:7/30/2015)... ... 2015 , ... The 2015 Market Research Report on the Global Propanol ... global Propanol market with a focus on the Chinese situation. Major companies included in ... ISU Chemical, Sanofi, Royal Dutch Shell, LG Chem and Zhejiang Xinhua Chemical. , The ...
Breaking Biology Technology:Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2Tronics appoints Francois Vieillard as Sales and Marketing Director 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3
... CryoLife, Inc. (NYSE: CRY ),a biomaterials, medical ... A. Theodore has been named vice president, general,counsel, ... directly to,Steven G. Anderson, chairman, president and chief ... Mr. Theodore will be responsible for all corporate,legal ...
... Dr. Andreas Krause to Present on Statistical Considerations for Model, ... and Simulation ... ... (OTC Bulletin Board: PHST), a leading provider of software and,strategic ...
... The 100 Most-Promising Private Technology Ventures Celebrated at Event in ... ... Sept. 3 /Xinhua-PRNewswire/ -- Red Herring,Magazine announced that the leading China ... winner of the,prestigious ,Red Herring 100 Asia, 2007 awards. The news ...
Cached Biology Technology:CryoLife Names Philip Theodore as Vice President, General Counsel 2Pharsight to Present at ROeS Seminar in Bern, Switzerland on September 10 & 11, 2007 2Pharsight to Present at ROeS Seminar in Bern, Switzerland on September 10 & 11, 2007 3Miaxis Biometrics Named as 'Red Herring 100 Asia' Award Winner for 2007 2Miaxis Biometrics Named as 'Red Herring 100 Asia' Award Winner for 2007 3
(Date:7/8/2015)... , N.J. and NEW YORK , July ... Guidepoint today announced BD & Guidepoint ... companies with free access to Guidepoint,s expert network services. ... that are developing cutting-edge technologies to improve healthcare delivery ... Guidepoint research manager, each start-up entrepreneur will be able ...
(Date:7/7/2015)... DUBLIN , June 30, 2015 ... ) has announced the addition of the ... their offering. To this date, fingerprint ... biometric technology and fingerprint sensors are well developed. ... capacitive sensing technology. The domain of ...
(Date:7/2/2015)... 25, 2015 Research ... of the "Natural Language Processing Market by ... OCR, Pattern & Image Recognition) - Worldwide Forecast ... The key vendors occupying the market are ... Microsoft Corporation, NetBase Solutions, SAS Institute Inc., Verint ...
Breaking Biology News(10 mins):BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2
... people take the anticoagulant drug warfarin to prevent harmful clotting ... proper dose of warfarin can vary greatly and can be ... to a recently identified gene involved in blood clotting, according ... of The New England Journal of Medicine. , By looking ...
... researchers showed that a fruit fly gene is crucial ... and how the transformation initially proceeds. Understanding this process ... surly teenagers. , When the DHR4 gene is disabled, ... larva to a sexually active adult. It is the ...
... biochemical pathways that plants use to defend themselves against ... of each other. , Knowing how these pathways of ... that can better resist a variety of pathogens, said ... professor of horticulture and crop science at Ohio State ...
Cached Biology News:Genetic variation alters response to common anti-clotting drug 2Genetic variation alters response to common anti-clotting drug 3MWG Biotech expands siMAX?siRNA portfolio with new scales, lengths and design tools 2MWG Biotech expands siMAX?siRNA portfolio with new scales, lengths and design tools 3MWG Biotech expands siMAX?siRNA portfolio with new scales, lengths and design tools 4Study: Plants use dual defense system to fight pathogens 2
Polaroid black & white positive, 3 x 4 inch pack film, ISO 3000/ 36 ASA DIN (20 expsures). For use in the Polaroid Direct Copy Camera (PHC34)....
Request Info...
SHEEP ANTI ECHIS OCCELATUS (VENOM)...
... ExcelGel DNA Analysis Kit, 1. ... and high resolution DNA typing. *Semi-dry ... and clean-up. *Precast, plastic-backed gels and ... convenience and detection sensitivity. Category: ...
Biology Products: